Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the recipient of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 80,100 shares, a drop of 30.8% from the May 15th total of 115,700 shares. Based on an average daily volume of 97,700 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.5% of the shares of the company are short sold.
Institutional Trading of Ikena Oncology
Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new stake in shares of Ikena Oncology during the 4th quarter valued at approximately $72,000. BNP Paribas Financial Markets acquired a new stake in Ikena Oncology during the fourth quarter worth $72,000. Northern Trust Corp raised its position in Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares during the period. BML Capital Management LLC lifted its stake in shares of Ikena Oncology by 395.8% in the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company's stock valued at $5,881,000 after purchasing an additional 2,862,578 shares during the last quarter. Finally, Gilead Sciences Inc. acquired a new position in shares of Ikena Oncology in the 4th quarter valued at $3,294,000. Institutional investors and hedge funds own 75.00% of the company's stock.
Ikena Oncology Stock Performance
Ikena Oncology stock traded down $0.01 during midday trading on Friday, hitting $1.36. 26,724 shares of the company were exchanged, compared to its average volume of 136,193. The business has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $1.37. The firm has a market capitalization of $65.63 million, a PE ratio of -1.58 and a beta of 0.45. Ikena Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $1.94.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. As a group, equities analysts expect that Ikena Oncology will post -0.91 earnings per share for the current year.
About Ikena Oncology
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Further Reading
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
